Do these drugs cause cancer — the three separate questions hiding inside one headline

“Does Ozempic cause cancer” is a single search term covering three unrelated questions, each with a different evidence base and a different answer.

Untangling them is worth doing, because the honest overall picture is considerably more reassuring than the headlines — and in one direction, actively encouraging.

Question one: the thyroid warning

This is the only one with a regulatory consequence, and it has a clear practical answer.

Rodents given GLP-1 agonists developed C-cell hyperplasia and medullary thyroid carcinoma. Rodent thyroid C-cells carry far more GLP-1 receptors than human ones do, non-human primates did not develop the tumours, and fifteen years of human surveillance has not confirmed an equivalent risk.

It reduces to one rule: anyone with a personal or family history of medullary thyroid carcinoma, or with MEN2, must not take these drugs. That contraindication is absolute and it is not about ordinary hypothyroidism, thyroid nodules or papillary thyroid cancer. The full treatment is in the thyroid cancer warning.

Question two: pancreatic cancer

This concern is older than the current drugs and attaches to the incretin class generally.

It arose around 2013 from retrospective database analyses and adverse event reporting. It has since been examined in every large cardiovascular outcome trial in the class — randomised, prospective, adjudicated — without confirmation.

There is also a specific methodological trap here that explains a good deal of the early signal. Pancreatic cancer causes diabetes. It can also cause weight loss. So a person developing undiagnosed pancreatic cancer may be prescribed a diabetes or weight drug in the months before diagnosis, and appear in the data as a drug user who developed cancer. That is reverse causation, and pancreatic cancer is one of the classic settings for it.

The related but separate question of acute pancreatitis — a different condition entirely — is covered in pancreatitis on a GLP-1.

Question three: the direction nobody expects

Here is the part that rarely makes the headline.

The International Agency for Research on Cancer concluded that body fatness is causally associated with at least thirteen cancers — among them oesophageal adenocarcinoma, gastric cardia, colorectal, liver, gallbladder, pancreatic, breast in postmenopausal women, endometrial, ovarian, kidney, thyroid, meningioma and multiple myeloma.

Obesity is one of the largest modifiable causes of cancer after smoking.

If a drug produces fifteen to twenty percent sustained weight loss, the reasonable prior is that it should reduce the incidence of at least some of those cancers. Observational analyses comparing GLP-1 users with users of other diabetes drugs have generally pointed that way, finding lower rates across several obesity-associated cancers.

That evidence is observational and carries every limitation observational evidence carries. But the mechanism is not speculative, and the direction of the effect is the opposite of what the public conversation assumes.

What this means if you have had cancer

A cancer history is not a blanket contraindication, with the medullary thyroid exception noted above. It is a conversation.

Points worth raising with your oncology team:

• Weight management is part of survivorship care for several obesity-associated cancers, particularly breast and endometrial
• Unintentional weight loss during or after cancer treatment is a different problem entirely, and appetite suppression is unhelpful in someone already struggling to maintain weight
• Muscle preservation matters more in anyone deconditioned by treatment, which makes protein and resistance training non-optional rather than advisable
• Timing relative to active treatment and to any planned surgery — see GLP-1s before surgery

How to read the next scare

There will be another one. A useful checklist:

Randomised or observational? Observational studies in this field are heavily confounded by indication.

Could reverse causation explain it? Especially for cancers that themselves cause weight loss or diabetes.

Is it detection bias? People starting a new injectable get more medical attention and more incidental findings than people who do not.

What is the absolute risk? A large relative increase in a rare event is still a rare event — the arithmetic in the gallstone piece is the clearest worked example on this site.

Has anyone reproduced it? A single database analysis is a hypothesis. The same discipline applied to the eye risk signal is worth reading alongside this.

The summary

One rodent finding, faithfully carried onto a human label for fifteen years and unconfirmed in people. One old scare that prospective data has not supported. And one large, well-established causal relationship between obesity and cancer that these drugs are plausibly reducing.

That third item is the one with the best evidence behind it, and it is the one nobody puts in a headline.